31 Results for "

glycoprotein-IIb

" in MedChemExpress (MCE) Product Catalog:
Products (31)

31 Results for "glycoprotein-IIb" in MCE Product Catalog:

9
9 Publications Verification
Cat. No.: HY-B0686
CAS No.: 188627-80-7
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
loading...
    loading...
9
9 Publications Verification
Cat. No.: HY-B0686B
CAS No.: 881997-86-0
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P0074
CAS No.: 67869-62-9
Synonyms: Gly-Pro-Arg-Pro; Pefa 6003
Target:  

Thrombin

Research Areas:  

Cardiovascular Disease

GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P0074A
CAS No.: 157009-81-9
Synonyms: Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P9934
CAS No.: 143653-53-6
Synonyms: C7E3

Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
loading...
    loading...
Cat. No.: HY-146332
CAS No.: 104260-73-3
Target:  

P-selectin

Research Areas:  

Cardiovascular Disease

Collagen-IN-1 (compound 3), an ortho-carbonyl hydroquinone derivative, is a selective inhibitor on collagen. Collagen-IN-1 inhibits agonist-induced platelet aggregation in a non-competitive manner with an IC50 value of 1.77 μM. Collagen-IN-1 reduces the expression of P-selectin, activation of glycoprotein IIb/IIIa, and release of adenosine triphosphate and CD63 from platelet. Collagen-IN-1 has the potential for platelet-related thrombosis diseases research .
loading...
    loading...
Cat. No.: HY-B0686A
CAS No.: 1248559-53-6
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
loading...
    loading...
Cat. No.: HY-10305
CAS No.: 149820-74-6
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Xemilofiban is an orally active glycoprotein IIb/IIIa blocking agent. Xemilofiban inhibits platelet aggregation. Xemilofiban reduces the incidence of thrombosis .
loading...
    loading...
Cat. No.: HY-10309
CAS No.: 172927-65-0
Purity:  99.67%
Synonyms: RO 48-3657
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation .
loading...
    loading...
Cat. No.: HY-10309R
CAS No.: 172927-65-0
Synonyms: RO 48-3657 (Standard)
Research Areas:  

Cardiovascular Disease

Sibrafiban (Standard) is the analytical standard of Sibrafiban. This product is intended for research and analytical applications. Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation .
loading...
    loading...
Cat. No.: HY-101720
CAS No.: 148396-36-5
Synonyms: BIBU-52
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
loading...
    loading...
Cat. No.: HY-101720A
Purity:  99.96%
Synonyms: BIBU-52 hydrochloride
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
loading...
    loading...
Cat. No.: HY-10308
CAS No.: 149503-79-7
Target:  

Integrin

Research Areas:  

Metabolic Disease

Lefradafiban is an orally active glycoprotein IIb/IIIa receptor antagonist. Lefradafiban can be metabolized to its active form, Fradafiban, a non-peptide GP IIb/IIIa receptor antagonist .
loading...
    loading...
Cat. No.: HY-111348
CAS No.: 144412-49-7
Synonyms: Ro 44-9883
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes .
loading...
    loading...
Cat. No.: HY-108881R
CAS No.: 2751-09-9
Synonyms: Triacetyloleandomycin (Standard)
Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
loading...
    loading...
Cat. No.: HY-B0686BR
CAS No.: 881997-86-0
Research Areas:  

Cardiovascular Disease

Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .
loading...
    loading...
Cat. No.: HY-111348A
CAS No.: 144412-50-0
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes .
loading...
    loading...
Cat. No.: HY-U00235
CAS No.: 180144-61-0
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
loading...
    loading...
Cat. No.: HY-126039
CAS No.: 168157-33-3
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

L-739758 is an antagonist for αIIbβ3 integrin (platelet glycoprotein IIb/IIIa). L-739758 acts as a peptidomimetic, binds to αIIbβ3 integrin by mimicking the interaction of the RGD (arginine-glycine-aspartic acid) motif, and is involved in the blood coagulation process. L-739758 inhibits platelet aggregation, and is used for thrombosis research .
loading...
    loading...
Cat. No.: HY-P3082
CAS No.: 126053-71-2
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .
loading...
    loading...